GIANT CELL ARTERITIS (GCA)
Clinical trials for GIANT CELL ARTERITIS (GCA) explained in plain language.
Never miss a new study
Get alerted when new GIANT CELL ARTERITIS (GCA) trials appear
Sign up with your email to follow new studies for GIANT CELL ARTERITIS (GCA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New injection aims to tame dangerous blood vessel inflammation
Disease control CompletedThis study tested whether adding a medication called secukinumab to standard steroid treatment could better control giant cell arteritis, a serious inflammatory disease of blood vessels. It involved 354 adults with the condition and compared two doses of the injected drug against…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
French data reveals which arthritis drug better shields patients from heart attacks and strokes
Disease control CompletedThis study looked back at French health records to compare two drugs—tocilizumab and methotrexate—for treating giant cell arteritis, a serious inflammatory condition. Researchers wanted to see which medication better protected patients from major heart problems like heart attacks…
Matched conditions: GIANT CELL ARTERITIS (GCA)
Sponsor: Groupe français d'étude des Maladies Inflammatoires de loeil • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New drug shows promise for controlling dangerous blood vessel inflammation
Disease control CompletedThis study tested whether adding the medication upadacitinib to steroid treatment could help people with giant cell arteritis achieve and maintain remission. 429 participants with this inflammatory blood vessel condition were randomly assigned to receive either the study drug or …
Matched conditions: GIANT CELL ARTERITIS (GCA)
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC